Contrast Agents and Radiopharmaceuticals | US | 2015 | Market Analysis
The US market for contrast agents and radiopharmaceuticals will be limited by reimbursement restrictions and lower dosing; nonetheless, growth in the large radiopharmaceutical market and favorable demographics will result in a modest expansion of the market through 2023.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals across a 10-year period.